KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2025)

Recursion Pharmaceuticals' Share-based Compensation history spans 6 years, with the latest figure at $23.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 22.81% year-over-year to $23.8 million; the TTM value through Dec 2025 reached $111.2 million, up 36.16%, while the annual FY2025 figure was $111.2 million, 36.16% up from the prior year.
  • Share-based Compensation reached $23.8 million in Q4 2025 per RXRX's latest filing, down from $25.2 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $36.1 million in Q1 2025 to a low of $1.8 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $14.5 million, with a median of $13.9 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: skyrocketed 591.42% in 2021, then decreased 22.81% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $4.3 million in 2021, then soared by 77.26% to $7.7 million in 2022, then soared by 109.04% to $16.1 million in 2023, then skyrocketed by 91.37% to $30.8 million in 2024, then fell by 22.81% to $23.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Share-based Compensation are $23.8 million (Q4 2025), $25.2 million (Q3 2025), and $26.2 million (Q2 2025).